Multi-domain Online Therapeutic Investigation Of Neurocognition (MOTION)
NCT05217849, Not applicable, Completed, University of California, San Francisco
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Multi-domain Online Therapeutic Investigation Of Neurocognition (MOTION) | ClinicalTrials.gov |
| NCT number | NCT05217849 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 77 participants, actual | ClinicalTrials.gov |
| Lead sponsor | University of California, San Francisco | ClinicalTrials.gov |
| Conditions | Mild Cognitive Impairment, Subjective Memory Decline | ClinicalTrials.gov |
| Interventions | Tai Chi, Preventing Loss of Independence through Exercise (PLIE), Health and Wellness Education | ClinicalTrials.gov |
| First posted | 2022-02-01 | ClinicalTrials.gov |
| Last updated | 2026-02-09 | ClinicalTrials.gov |
Registered outcomes 21
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog) Scores | Change from baseline to 1-week post-treatment. | The Alzheimer's Disease Assessment Scale-Cognitive Subscale is a brief neuropsychological assessment used to assess the severity of cognitive symptoms of dementia. ADAS-cog scores range from 0-70, with higher scores (≥ 18) indicating greater cognitive impairment. | ClinicalTrials.gov |
| Primary | Change in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog) Scores | Change from baseline to 6 months after treatment ends. | The Alzheimer's Disease Assessment Scale-Cognitive Subscale is a brief neuropsychological assessment used to assess the severity of cognitive symptoms of dementia. ADAS-cog scores range from 0-70, with higher scores (≥ 18) indicating greater cognitive impairment. | ClinicalTrials.gov |
| Primary | Change in Default Mode Network (DMN) functional connectivity | Change from baseline to 1-week post-treatment. | The default mode network (DMN) is a system of connected brain areas that show increased activity when a person is not focused on what is happening around them. Instead, the DMN is especially active when a person is engaged in introspective activities (e.g., daydreaming, or contemplating the past or future). Research suggests that the DMN is disrupted in people with Mild Cognitive Impairment (MCI) and Alzheimer's disease (AD). Functional connectivity can be defined as the similarity between brain signals that arise from two anatomically separated brain regions. Similarity between the brain signals can be analyzed using Pearson's correlation. | ClinicalTrials.gov |
| Secondary | Change in Auditory Memory scores | Change from baseline to 1 week post-treatment. | The stories subtest of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) will be used to assess auditory memory. Raw scores will be transformed to z-scores (with a mean of 0 and standard deviation of 1) for each test score of interest across all participants. Thus the sample mean (across all arms) is zero for each test score. The z-scores were then averaged to produce a composite scores. Higher scores are indicative of better performance. | ClinicalTrials.gov |
| Secondary | Change in Auditory Memory scores | Change from baseline to 6 months after treatment ends. | The stories subtest of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) will be used to assess auditory memory. Raw scores will be transformed to z-scores (with a mean of 0 and standard deviation of 1) for each test score of interest across all participants. Thus the sample mean (across all arms) is zero for each test score. The z-scores were then averaged to produce a composite scores. Higher scores are indicative of better performance. | ClinicalTrials.gov |
| Secondary | Change in Attention/Executive Function Cognitive Domain Scores | Change from baseline to 1-week post-treatment. | Neuropsychological tests will included the following domains: Attention/Executive Function (Trail Making Test A and B, Stroop Interference \[Golden version\]) Raw scores will be transformed to z-scores (with a mean of 0 and standard deviation of 1) for each test score of interest across all participants. Thus the sample mean (across all arms) is zero for each test score. The z-scores will be averaged to produce composite scores. Higher scores are indicative of better performance. | ClinicalTrials.gov |
| Secondary | Change in Attention/Executive Function Cognitive Domain Scores | Change from baseline to 6 months after treatment ends. | Neuropsychological tests will included the following domains: Attention/Executive Function (Trail Making Test A and B, Stroop Interference \[Golden version\]) Raw scores will be transformed to z-scores (with a mean of 0 and standard deviation of 1) for each test score of interest across all participants. Thus the sample mean (across all arms) is zero for each test score. The z-scores will be averaged to produce composite scores. Higher scores are indicative of better performance. | ClinicalTrials.gov |
| Secondary | Change in Verbal Fluency scores | Change from baseline to 1-week post-treatment. | Controlled Oral Word Association test (FAS). Raw scores will be transformed to z-scores (with a mean of 0 and standard deviation of 1) for each test score of interest across all participants. Thus the sample mean (across all arms) is zero for each test score. Higher scores are indicative of better performance. | ClinicalTrials.gov |
| Secondary | Change in Verbal Fluency scores | Change from baseline to 6 months after treatment ends. | Controlled Oral Word Association test (FAS). Raw scores will be transformed to z-scores (with a mean of 0 and standard deviation of 1) for each test score of interest across all participants. Thus the sample mean (across all arms) is zero for each test score. Higher scores are indicative of better performance. | ClinicalTrials.gov |
| Secondary | Change in Processing Speed Scores | Change from baseline to 1-week post-treatment. | Processing speed will be assessed with the coding subtest of RBANS as well as the Digit Symbol Substitution Test (DSST). Raw scores will be transformed to z-scores (with a mean of 0 and standard deviation of 1) for each test score of interest across all participants. Thus the sample mean (across all arms) is zero for each test score. The z-scores will be averaged to produce composite scores. Higher scores are indicative of better performance. | ClinicalTrials.gov |
| Secondary | Change in Processing Speed Scores | Change from baseline to 6 months after treatment ends. | Processing speed will be assessed with the coding subtest of RBANS as well as the Digit Symbol Substitution Test (DSST). Raw scores will be transformed to z-scores (with a mean of 0 and standard deviation of 1) for each test score of interest across all participants. Thus the sample mean (across all arms) is zero for each test score. The z-scores will be averaged to produce composite scores. Higher scores are indicative of better performance. | ClinicalTrials.gov |
| Secondary | Change in Mobility | Change from baseline to 1-week post-treatment. | Mobility will be assessed with the Timed Up and Go (TUG) test, which assesses the time it takes participants to stand up from a chair, walk 3 meters, turn around, walk back to the chair and sit down. In addition, we will assess steady-state gait during 90 seconds of continuous over-ground walking at normal preferred speed, with and without the addition of a dual task challenge (counting backward by one or by two). | ClinicalTrials.gov |
| Secondary | Change in Mobility | Change from baseline to 6 months after treatment ends. | Mobility will be assessed with the Timed Up and Go (TUG) test, which assesses the time it takes participants to stand up from a chair, walk 3 meters, turn around, walk back to the chair and sit down. In addition, we will assess steady-state gait during 90 seconds of continuous over-ground walking at normal preferred speed, with and without the addition of a dual task challenge (counting backward by one or by two). | ClinicalTrials.gov |
| Secondary | Change in Salience Network functional connectivity | Change from baseline to 1-week post-treatment. | The Salience Network consists of a network of brain regions whose cortical hubs are the anterior cingulate and ventral anterior insular (i.e., frontoinsular) cortices. This network also includes nodes in the amygdala, hypothalamus, ventral striatum, thalamus, and specific brainstem nuclei. | ClinicalTrials.gov |
| Secondary | Change in Language Network functional connectivity | Change from baseline to 1-week post-treatment. | The Language Network consists of a group of left-lateralized frontal and temporal brain regions that responds to written/spoken/signed words and sentences, but not to mental arithmetic, music perception, executive function tasks, or action/gesture perception. | ClinicalTrials.gov |
| Other | Change in PROMIS-29 Health-Related Quality of Life (HRQoL) Domains | Change from baseline to 1 week post-treatment. | The PROMIS-29 includes seven HRQoL domains: Physical Functioning, Anxiety, Depression, Fatigue, Sleep Disturbance, Social Functioning, and Pain). The pain domain has two subdomains (interference and intensity). Each of the 7 domains has four 5-level items (i.e., 16 decrements each). In addition to these items, pain intensity is assessed using a single 11-point numeric rating scale anchored between no pain (0) and worse imaginable pain (10), adding 10 additional decrements. | ClinicalTrials.gov |
| Other | Change in PROMIS-29 Health-Related Quality of Life (HRQoL) Domains | Change from baseline to 6 months after treatment ends. | The PROMIS-29 includes seven HRQoL domains: Physical Functioning, Anxiety, Depression, Fatigue, Sleep Disturbance, Social Functioning, and Pain). The pain domain has two subdomains (interference and intensity). Each of the 7 domains has four 5-level items (i.e., 16 decrements each). In addition to these items, pain intensity is assessed using a single 11-point numeric rating scale anchored between no pain (0) and worse imaginable pain (10), adding 10 additional decrements. | ClinicalTrials.gov |
| Other | Change in measures of body awareness | Change from baseline to 1-week post-treatment. | We will examine 3 measures of body awareness: Interoceptive attention is the ability to sustain and control attention to body sensations. Interoceptive self-regulation is the ability to regulate distress by attention to body sensations. These two measures will be assessed with MAIA-2 self-report questionnaire. We will also utilize the Body Awareness portion of the Body Experience Questionnaire to measure interoceptive attention/awareness. | ClinicalTrials.gov |
| Other | Change in measures of body awareness | Change from baseline to 6 months after treatment ends. | We will examine 3 measures of body awareness: Interoceptive attention is the ability to sustain and control attention to body sensations. Interoceptive self-regulation is the ability to regulate distress by attention to body sensations. These two measures will be assessed with MAIA-2 self-report questionnaire. We will also utilize the Body Awareness portion of the Body Experience Questionnaire to measure interoceptive attention/awareness. | ClinicalTrials.gov |
| Other | Change in a measure of mindfulness | Change from baseline to 1-week post-treatment. | Mindfulness will be assessed with the Freiburg Mindfulness Index (FMI), a valid and reliable 30-item questionnaire measuring mindfulness. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|---|---|
| 39809343 | DERIVED | PubMed |
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 5
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
| Symbol Coding | Secondary outcome | ConductCognition |
| Trail Making Test A | Secondary outcome | ConductCognition |
| Trail Making Test B | Secondary outcome | ConductCognition |
| Verbal Fluency | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)